Simplify Asset Management Inc. Invests $5.22 Million in Abivax SA Sponsored ADR $ABVX

Simplify Asset Management Inc. acquired a new stake in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 61,449 shares of the company’s stock, valued at approximately $5,217,000.

Other hedge funds also recently bought and sold shares of the company. Bank of America Corp DE boosted its holdings in shares of Abivax by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after purchasing an additional 1,990 shares during the last quarter. Cubist Systematic Strategies LLC boosted its stake in Abivax by 34.3% during the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after buying an additional 2,595 shares during the last quarter. XTX Topco Ltd purchased a new stake in Abivax in the 2nd quarter valued at $139,000. Quadrature Capital Ltd purchased a new stake in Abivax in the 2nd quarter valued at $148,000. Finally, NewEdge Advisors LLC acquired a new stake in shares of Abivax in the 2nd quarter worth $230,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ABVX. Truist Financial set a $140.00 price objective on shares of Abivax in a report on Monday, November 24th. Barclays initiated coverage on Abivax in a research report on Monday, October 13th. They issued an “overweight” rating and a $142.00 price objective for the company. BTIG Research upped their price target on Abivax from $112.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, October 6th. Piper Sandler reissued an “overweight” rating and set a $142.00 price objective on shares of Abivax in a research report on Tuesday, December 16th. Finally, Citigroup restated an “outperform” rating on shares of Abivax in a report on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $128.73.

Abivax Stock Down 1.3%

NASDAQ:ABVX opened at $140.40 on Tuesday. Abivax SA Sponsored ADR has a 52 week low of $4.77 and a 52 week high of $148.83. The stock’s fifty day moving average is $114.53 and its two-hundred day moving average is $78.02. The stock has a market capitalization of $10.94 billion, a price-to-earnings ratio of -33.59 and a beta of 0.49. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.03.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings data on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The firm had revenue of ($4.92) million during the quarter. Research analysts anticipate that Abivax SA Sponsored ADR will post -2.83 EPS for the current year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.